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Hematopoietic stem cells (HSCs) develop from a
specialized subpopulation of endothelial cells known
as hemogenic endothelium (HE). Although the HE
origin of HSCs is now well established in different
species, the signaling pathways that control this
transition remain poorly understood. Here, we
show that activation of retinoic acid (RA) signaling
in aorta-gonad-mesonephros-derived HE ex vivo
dramatically enhanced its HSC potential, whereas
conditional inactivation of the RA metabolizing
enzyme retinal dehydrogenase 2 in VE-cadherin ex-
pressing endothelial cells in vivo abrogated HSC
development. Wnt signaling completely blocked the
HSC inductive effects of RA modulators, whereas
inhibition of the pathway promoted the development
of HSCs in the absence of RA signaling. Collectively,
these findings position RA and Wnt signaling as key
regulators of HSC development and in doing so
provide molecular insights that will aid in devel-
oping strategies for their generation from pluripotent
stem cells.
INTRODUCTION
In themouse embryo, hematopoietic stem cells (HSCs) are spec-
ified in the aorta-gonad-mesonephros (AGM) between embry-
onic day (E) 10.5 and 11.5 through a sequence of developmental
events that involves the transition of a specialized endothelial
population known as hemogenic endothelium (HE)/pre-HSCs
to hematopoietic progenitors, a process commonly referred as
the endothelial to hematopoietic transition (EHT) (Medvinsky
and Dzierzak, 1996; Yoshimoto and Yoder, 2009). During this
transition, the developing hematopoietic cells undergo morpho-
logical changes, ‘‘bud’’ from the HE, and form distinct clusters
that can be detected within the lumen of the aorta (Bertrand
et al., 2010; Boisset et al., 2010; Eilken et al., 2009). The HE
and early hematopoietic progeny share the expression of many
endothelial and hematopoietic markers and transcription fac-tors, including VEC, AA4.1, CD31, Runx1, Gata2, and Scl/Tal1
(Bertrand et al., 2005; Chen et al., 2009b; Lancrin et al., 2009;
Ren et al., 2010; Schlaeger et al., 2005; Taoudi et al., 2008;
Tsai et al., 1994; Yokomizo et al., 2001) These populations
can, however, be distinguished by expression of the pan
hematopoietic marker CD45 because its levels are upregulated
with the transition to a hematopoietic fate. Given these differ-
ences, emerging HSCs can be identified and isolated from the
AGM of appropriately staged embryos based on the coexpres-
sion of VEC/AA4.1 and CD45 (Bertrand et al., 2005; Lancrin
et al., 2009; Taoudi et al., 2008; Taoudi et al., 2005). Once formed
in the AGM, it is thought that the HSCs seed the fetal liver where
the population expands prior to moving to the bone marrow late
in fetal life.
Expression analyses and gene targeting studies have identi-
fied key transcription factors that play a role in HSC development
and in doing so have begun to define the transcriptional regula-
tory network that controls this developmental progression (Zon,
2008). The findings from these studies position Runx1 as a cen-
tral player in this process because it is expressed within the HE
and newly formed hematopoietic cells and it is essential for the
EHT and consequently for HSC development (Chen et al.,
2009b; Mukouyama et al., 2000; Wang et al., 1996; Yokomizo
et al., 2001). Additionally, Gata2 and Gata3, Scl/Tal1, members
of the Hox family, and Sox17 are also expressed to varying
degrees in the early vasculature, the HE, and early hematopoietic
progenitors and have been shown to play a role in the develop-
ment of functional HSCs (Antonchuk et al., 2002; Clarke et al.,
2013; Fitch et al., 2012; Mikkola et al., 2003; Tsai et al., 1994).
In contrast to our understanding of transcriptional regulation of
hematopoietic development, the signaling pathways that control
these early events are not well defined. Components of different
pathways including Notch, Wnt, IL-3, Hedgehog, and BMPs are
expressed in the region of the aorta that gives rise to HE and
hematopoietic progenitors, suggesting they play some role in
this process (Kaimakis et al., 2013). Of these, the Notch and
Wnt pathways have been shown to be required for HSC develop-
ment in vivo (Hadland et al., 2004; Kumano et al., 2003; Ruiz-
Herguido et al., 2012).
In addition to these regulators, retinoic acid (RA) signaling is of
interest in the context of embryonic hematopoiesis as it is
known to function in many different lineages at multiple stagesCell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc. 215
of development and recent studies have shown that activation of
the pathway can impact hematopoietic development in zebrafish
and embryonic stem cell differentiation cultures (de Jong et al.,
2010; Yu et al., 2010). RA signaling is mediated through one of
the three retinoic acid receptors (RAR) -a, -b, and -g that form
hetero-dimerized complexes with the rexinoid receptors (RXR)
-a, -b, and -g (Rhinn and Dolle´, 2012). Signaling is initiated
following binding of the ligand all-trans retinoic acid (ATRA), a
derivative of Vitamin A, and results in activation of downstream
target genes (Balmer and Blomhoff, 2002, 2005; Duester,
2008). As ATRA acts at short distances, it is synthesized at
the site of action, often in the responding cells, by one of the
three different retinal dehydrogenases (Raldh-1, -2 and -3)—a
subclass of aldehyde dehydrogenases (Duester, 2008; Kumar
et al., 2012).
Both the RARs and the Raldhs are widely expressed
throughout embryonic development, including the hematopoi-
etic tissues (Duester, 2008; Kumar et al., 2012). Despite these
patterns, targeting studies failed to uncover any gross hemato-
logical defects in RAR-a, RAR-g, Raldh1, and Raldh3 null
embryos, suggesting that either the pathway is not essential
for embryonic hematopoietic development or that compensa-
tory mechanisms masked the function of these individual
receptors and enzymes. Raldh2 null embryos, in contrast,
show hematovascular defects in the yolk sac (YS) at E9.5, sug-
gesting that the pathway does play some role in hematopoietic
development (Goldie et al., 2008; Niederreither et al., 1999).
Detailed analyses of AGM hematopoiesis or HSC development
was not, however, possible in these embryos as they die
between E9.0 and E10.5.
In this study we investigated the role of RA signaling in
hematopoietic development in the AGM and demonstrate that
this pathway is required for the generation of HSCs. We show
that activation of the pathway in isolated HE/pre-HSC popula-
tions in vitro dramatically enhanced the generation of HSCs,
whereas conditional deletion of Raldh2 in VEC+ endothelial cells
in vivo inhibited HSC development. We also provide evidence
that RAR-a is the effective RA pathway agonist for enhancement
of HSCs and that the effects are mediated through the Wnt/
b-catenin pathway. Together, these findings identify a pivotal
role for RA signaling in HSC development.
RESULTS
Expression of RARs and Raldhs in AGM-Derived
Hemogenic and Hematopoietic Populations
To determine whether RA signaling plays a role in embryonic
HSC development, we analyzed E10.5 and E11.5 AGM-derived
AA4.1+/VEC+ (E+) populations, known to contain HE (Bertrand
et al., 2005; Rybtsov et al., 2011) and HSCs, respectively
(Bertrand et al., 2005; Taoudi et al., 2008), for expression of ret-
inoic acid receptors (RAR) -a, -b, and -g that are functionally
required to mediate RA signaling (Rhinn and Dolle´, 2012). Intra-
cellular flow cytometric analyses revealed that RAR-a and
RAR-g were expressed in the majority of the E+ cells at
both time points, whereas expression of RAR-b appeared to
be restricted to only a subset of this population at E11.5 (Fig-
ure 1A available online). All RARs were also expressed in the216 Cell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc.AA4.1/VEC population (data not shown). Immunostaining
analyses further confirmed that RAR-a and RAR-g were ex-
pressed in the dorsal aorta region at E11.5 (Figure 1B). The
observation that RARs are expressed in these AGM popula-
tions supports the interpretation that RA signaling could play
a role in HSC development.
The presence of retinal dehydrogenases (Raldhs), the en-
zymes responsible for synthesizing RA is also an indication of
active RA signaling, as in many cases the cells that respond to
it also synthesize it (Duester, 1999, 2008). To determine whether
AGM-derived cells, including HSCs, display the capacity to syn-
thesize RA, the E+ fraction from E10.5 and E11.5 AGMs was
stained with aldefluor (Jones et al., 1995), a fluorescent com-
pound that measures the enzymatic activity of active aldehyde
dehydrogenases including retinal dehydrogenases (Kumar
et al., 2012). As shown in Figure 1C, aldefluor + (Aldh+) popula-
tions were detected within the E+ fraction of the AGM at both
time points, indicating that at least a subset of these cells
expresses functional aldehyde dehydrogenase(s). To further
characterize the enzyme activity in these cells, Aldh+ and Aldh
fractions from the E11.5 AGM-derived E+ population were
isolated by FACS and analyzed for expression of 15 aldehyde
dehydrogenases. As shown in Figure 1D, expression of Raldh
1, 2, and 3 segregated predominantly to the Aldh+ fraction,
whereas all other Aldhs, with the exception of 3B2, were ex-
pressed at equal levels in both fractions. These findings suggest
that the E+ population in the developing AGM has functional
retinal dehydrogenases and as such, further support the notion
that the RA signaling pathway is active in this region of the
embryo at this stage of development.
Aldefluor Activity Tracks with HSC Potential in the AGM
Previous studies have demonstrated that developing HSCs can
be isolated based on the coexpression of AA4.1+/VEC+ (E+) and
CD45+ (H+) (Taoudi et al., 2008). To determine if the developing
HSCs display aldehyde dehydrogenase activity, the AA4.1+/
VEC+CD45+ (E+H+) AGM fraction from E11.5 embryos was
stained with aldefluor, and the resulting Aldh+ and Aldh popu-
lations were isolated by FACS and transplanted into irradiated
Rag2/gc/ recipients (Figure 2A). At 16 weeks posttransplan-
tation, donor-derived hematopoietic cells were detected only in
mice transplantedwith the E+H+Aldh+ population (p < 0.01) indi-
cating that it contains all the HSC activity (Figures 2B and 2C).
Donor-derived lymphoid and myeloid cells were detected in all
primary hematopoietic organs in representativemice at 32weeks
posttransplantation, demonstrating multilineage repopulation
(Figure S1A). Bone marrow from the 32-week-old recipients
was able to repopulate secondary recipients, indicating the pres-
ence of long-term repopulating HSCs (Figure S1B). LDA revealed
a HSC frequency of 1 in 0.78 embryo equivalent (e.e.) in the
E+H+Aldh+ population (Tables S1 and S3). In contrast to
HSCs, progenitors as measured by colony formation in methyl-
cellulose, were detected in both populations. Interestingly,
higher levels of multi-and bipotential (Multilineage, GM) progen-
itors were present in the Aldh population (Figure 2D). Together,
these findings show that, at this stage, the AGM-derived HSCs
are Aldh+, whereas the majority of the progenitors segregate
to the Aldh fraction.
Figure 1. Retinoic Acid Receptors and
Retinal Dehydrogenases Are Expressed in
AGM-Derived HSC-Containing Populations
(A) Intracellular flow cytometry analysis of RAR
(-a, -b, and -g) in AA4.1+/VEC+ cells from the (i)
E10.5 and (ii) E115 AGM region.
(B) Immunohistochemistry of the dorsal-aorta
region (E11.5) stained with anti-RAR-a and RAR-g
antibodies.
(C) Aldefluor staining in AA4.1+/VEC+ cells from
E10.5 and E11.5 AGM.
(D) qRT-PCR analyses of aldehyde de-
hydrogenases, implicated in RA or non-RA syn-
thesis, in Aldh+ and Aldh cells sorted from the
E11.5 AGM-derived AA4.1+/VEC+ population.
Significant differences are indicated with aster-
isks, and error bars represent the SEM (*p < 0.05,
**p < 0.01, t test).Raldh2 Is Required for HSCs Formation
Access to the AGM subpopulations at different stages enables
one to establish a developmental progression transitioning
from E10.5 (E+Aldh and E+Aldh+) HE to E11.5 E+H+Aldh+Cell 155, 215–227, SeHSCs to E11.5 E+H+Aldh hematopoi-
etic progenitors (Figure 3A). qRT-PCR-
based expression analyses of these
populations revealed that genes associ-
ated with endothelial development, the
specification of hemogenic endothelium
(Notch), and the establishment of
definitive hematopoiesis (Hox, Scl, Aml)
were expressed at higher levels in the
E10.5 populations, and in the HSC
containing fraction (E+H+Aldh+) than in
the progenitor fraction (E+H+Aldh). In
contrast, genes associated with the
development of the hematopoietic line-
ages such as Gata1, Gata2, and the
hematopoietic specific genes CD41 and
CD45 were expressed at higher levels in
the E+H+Aldh fraction. Importantly,
the retinal dehydrogenases Aldh1a1
(Raldh1) and Aldh1a2 (Raldh2) were the
only genes whose expression tracked
with the HSC containing populations
(Figure 3A).
To test whether or not Raldh activity
plays a role in HSC development, we
deletedRaldh2 in VEC+ cells, by crossing
VEC-Cre and Raldh2-floxed mice as pre-
vious studies showed that Raldh2 null
mice display yolk sac hematopoietic
defects. The AGM, yolk sac (YS) and
placenta (PL) from Raldh2-deleted
(Raldh2f/f;VEC-Cre) and -nondeleted
(Raldh2f/+;VEC-Cre, Raldh2f/+, Raldh2f/f:
controls) embryos were assayed for
HSC potential (Figure 3B). As shown inFigures 3C and 3D, none of the recipients of the Raldh2f/f;VEC-
Cre AGM cells showed any repopulation indicating that this
enzyme is essential for the generation of the HSC at this site.
Two recipients from each of the YS and PL groups did containptember 26, 2013 ª2013 Elsevier Inc. 217
Figure 2. Aldehyde Dehydrogenase Activity Tracks with Emerging HSCs from the AGM
(A) Scheme for transplantation assay. E+H: AA4.1+/VEC+CD45; E+H+: AA4.1+/VEC+CD45+ (black dashed rectangle); EH+: AA4.1+/VEC-CD45+. The
aldefluor (Aldh) positive and negative fraction within E+H+ are identified as E+H+Aldh+ (gray solid rectangle) and E+H+Aldh (black solid rectangle), respectively.
Negative control, DEAB+Aldefluor, represents cells treated with the aldehyde dehydrogenase inhibitor DEAB.
(B) Engraftment potential of the E+H (solid triangle), E+H+Aldh+ (solid rectangle), E+H+Aldh (solid circle), and EH+ (solid diamond) fractions at 1 embryo
equivalent (e.e.) Significant difference from these combined fractions are indicated with asterisks (**p < 0.01, ANOVA and Dunnett’s postmultiple comparison
test). The dashed line represents 5% threshold level of donor-derived reconstitution, and error bars represent the SEM.
(C) Flow cytometric analysis to monitor donor-derived multilineage reconstitution in mice transplanted with E+H+Aldh+ cells.
(D) Methylcellulose-based colony assays measuring the progenitor potential of the E+H+Aldh (black solid bars) and E+H+Aldh+ (gray solid bars) populations
(*p < 0.05, t test). See also Figure S1 and Tables S1 and S3.significant numbers of donor cells, possibly reflecting incom-
plete deletion of the Raldh2 alleles. To address this, hematopoi-
etic colonies generated from CD45.2 sorted (donor) cells from
these recipients were analyzed by PCR (genomic) for the pres-
ence of the Raldh2 alleles. The outcome of this analysis revealed
that all of the colonies assayed (200) contained a nondeleted
allele, demonstrating that Raldh2 is required for HSC develop-
ment (Figure 3F).
Raldh2f/f;VEC-Cre embryos showed subtle anatomical abnor-
malities, including defective development of the head, but were
viable at E11.5, the time of HSC analyses, (Figure 3E). We did not
observe any striking defects in the dorsal aorta of these
embryos, suggesting the observed defect in repopulation fre-
quency was not due to perturbed endothelium (Figure S2A).
Together, these data demonstrate that Raldh2 is required for
HSC formation and/or function during embryogenesis.
RA Signaling via RAR-a Promotes HSC Development
To further investigate the role of RA signaling in HSC develop-
ment, the E11.5 AGM-derived VEC+/AA4.1+ (E+) population
was isolated by FACS, reaggregated and cultured for 8 hr in a
serum-free medium with either ATRA, a pan-RAR agonist, or
the RAR-a (AM580; Delescluse et al., 1991; Gianni et al., 1993),
-b (AC55649; Lund et al., 2005) or -g (CD437; Gianni et al.,
1993) receptor-specific agonists (Figure 4A). Following this cul-
ture step, the cells were transplanted into recipient mice at218 Cell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc.1 e.e. to determine if activation of the pathway influenced their
repopulation potential (Figure 4A). The entire AA4.1+/VEC+
(E+) fraction containing both the pre-HSC endothelial (AA4.1+/
VEC+CD45) and HSC (AA4.1+/VEC+ CD45+) populations
were used for these studies to maximize the potential progenitor
pool that could respond to these agonists. Culture with ATRA re-
sulted in a modest enhancement (p = 0.0501) in the proportion
(mean [m] = 15%) of donor cells and the frequency (f = 60%) of
repopulated recipients compared to the DMSO (m = 3.5%, f =
20%) control at both 16 (Figure 4B) and 32 weeks (data not
shown) posttransplant. Treatment with AM580 in contrast led
to a significant (p < 0.01) increase in both the proportion of donor
cells (m = 40%) and frequency (f = 100%) of recipients engrafted.
In contrast to AM580, neither CD437 nor AC55649 impacted
HSC development (Figure 4B and Table S1). These data suggest
that the impact of RA signaling on developing HSCs is mediated
primarily via RAR-a. To further demonstrate agonist specificity of
the effect, E+ cells were treated with ATRA in the absence and
presence of the RAR-a-specific antagonist (Ro-415253) (Apfel
et al., 1992). As shown in Figure 4C and Table S2, the addition
of the antagonist inhibited the effect of ATRA, providing further
evidence that the HSC inductive effect of RA signaling is primar-
ily mediated through RAR-a.
As RARs were also expressed in the E10.5 AGM-derived HE
progenitors (Figures 1A and 1B), and aldefluor activity was
observed at this stage (Figure 1C), we next asked whether RA
Figure 3. Retinoic Acid Signaling Is
Required for the Development of HSCs
(A) Heat-map identifying differential expression
of genes based on qRT-PCR analyses from
E10.5 E+Aldh (blue), E+Aldh+ (green), E11.5
E+H+Aldh+ (green) and E+H+Aldh (red) frac-
tions. Pre-HSC/hemogenic endothelium and HSC
containing fractions and Raldh1 (Aldh1a1) and
Raldh2 (Aldh1a2) expression are highlighted with
dashed lines. Biological replicates are indicated at
the left of each row, and genes are indicated on the
top of each column.
(B) Schematic for transplantation analyses. Bone
marrow-derived CD45.2+ cells, contributed by
Raldh2f/f; VEC-Cre embryos, were analyzed for the
presence or absence of a functional Raldh2 allele.
(C) Analysis of donor-derived PB in mice recon-
stituted at 1 e.e with HSCs from different regions
(AGM, YS, and PL) of Raldh2f/f; VEC-Cre, or con-
trol (Raldh2f/+; VEC-Cre, Raldh2f/f, or Raldh2f/+)
embryos (*p < 0.05, **p < 0.01, t test). Error bars
represent the SEM.
(D) Frequency of mice engrafted with > 5% donor-
derived cells with Raldh2f/f; VEC-Cre or control
embryos (Raldh2f/+; VEC –Cre, or Raldh2f/f, or
Raldh2f/+).
(E) Morphology ofRaldh2f/f; VEC-Cre andRaldh2f/f
embryos. White asterisks indicate abnormal
morphology in the Raldh2f/f; VEC-Cre embryo.
(F) Polymerase chain reaction (PCR) genotyping of
single colonies picked from methylcellulose cul-
tures generated from the bonemarrow (CD45.2) of
placental cell recipients (CD45.1). The size of the
WT (+), floxed (f) and deleted (D) Raldh2 alleles are
depicted with arrows. Number (#) of colonies with
D/D genotype is indicated at the bottom. See also
Figure S2 and Table S1.signaling could impact HSC development from HE using the
approach outlined in Figure 5A, i. Treatment of the E10.5 E+ pop-
ulation with AM580 resulted in a striking enhancement of HSC
potential as shown by both higher levels of donor-derived cells
(m = 35.6%, p < 0.05) and increased proportion of repopulated
recipients (f = 83.3%) compared to the DMSO control (m =
3.2%, f = 33.3%) (Figure 5B). Culture with CD437 again had no
effect (Figure 5B) and AC55649 was not tested given the low
level of RAR-b expression at this stage (Figure 1B). Consistent
with the transplantation analyses, AA4.1+/VEC+ progenitors
cultured with ATRA and AM580 generated more AA4.1+/VEC+
CD45+ cells than those cultured with DMSO-treated cells (Fig-
ures S2B and S2C). LDA revealed that treatment with AM580
resulted in an approximate 5-fold increase in HSC numbersCell 155, 215–227, Secompared to the DMSO control (p =
0.000068) (Figure 5C and Tables S1 and
S4). The findings from this set of experi-
ments strongly suggest that RA signaling
does function to promote HSC develop-
ment from HE in the AGM region.
Given that the AM580 treatment
showed striking HSC inductive effects
and that the Raldh2 deletion resulted inthe complete abrogation of HSC development, we next deter-
mined if exogenous addition of the RAR-a agonist could rescue
the HSC phenotype of Raldh2f/f;VEC-Cre embryos. To address
this, the AGM regions of E10–E10.5 Raldh2f/f;VEC-Cre embryos
were isolated, pooled, and cultured with AM580 or DMSO prior
to transplantation (Figure S2D). Treatment with AM580 did
appear to rescue some HSC potential as two out of six recipients
showed repopulation at 12 weeks posttransplantation. In
contrast, none of the recipients that received cells cultured in
DMSO were engrafted (Figure S2E). Using the same approach
outlined in Figure 3B, we verified the genomic deletion of the
Raldh2 alleles in hematopoietic colonies generated from
CD45.2 (donor) cells isolated from the engrafted recipients
(data not shown). These findings indicate that AM580 can rescueptember 26, 2013 ª2013 Elsevier Inc. 219
Figure 4. Retinoic Acid Signaling via RAR-a
Promotes HSC Development
(A) Transplantation assay scheme. E+ (AA4.1+/
VEC+) cells isolated from E11.5 WT embryos
(CD45.1) were cultured as aggregates with
modulators of RA signaling for 8 hr, and then
transplanted at 1 e.e. intrafemorally into CD45.2
Rag2/gc/ recipients.
(B) Engraftment as assessed by flow cytometry on
peripheral blood (PB) to detect donor-derived
(CD45.1+) cells at 16 weeks or more post-
transplantation. Each point represents a single
recipient. Repopulated mice are those containing
5% or more donor-derived cells (dotted line).
Error bars represent the SEM. Frequency of mice
with > 5% donor-derived chimerism in each group
is shown at the top of each treatment panel.
Significant difference is indicated with asterisks
(**p < 0.01, ANOVA, and Dunnett’s postmultiple
comparison with UNT or DMSO as comparative
column).
(C) Limiting dilution analysis (LDA) showing re-
populating potential of 1 and 3 e.e. E+ cells treated
with ATRA, either in the presence (solid gray circle) or absence (solid black circle) of the RAR-a antagonist Ro-415253 (10 mM). Solid black and gray lines
represent the mean of the ATRA, and ATRA+Ro-415253 treatments, respectively, whereas the dotted lines represent 95% confidence interval of the same
(p = 0.00389, ELDA). See also Figures S1 and S3 and Tables S1 and S2.the HSC potential in the Raldh2 null embryos, further demon-
strating that the RA pathway is required for HSC development.
As a subpopulation of the E10.5 E+ fraction is aldefluor posi-
tive, it is possible that this activity also marks pre-HSCs/HE. To
investigate this possibility, the E+Aldh+ and E+Aldh popula-
tions were isolated and cultured with AM580 or DMSO, and sub-
sequently transplanted into recipient mice (Figure 5A,ii). As
shown in Figure 5D, the effects of the RAR-a agonist on
HSC development were observed predominantly in the E10.5
AGM-derived E+Aldh+ fraction (m = 25%, p < 0.01; f = 77.7%)
demonstrating that Aldh activity at this stage does identify the
subpopulation of HE that responds to RA signaling and gener-
ates HSCs.
RA Signaling Promotes HSC Development through the
Transient Downregulation of Wnt Signaling
To better understand the signaling pathways that could regu-
late HSC development, we next performed microarray profiling,
comparing the E11.5 AGM-derived E+H+ (HSC containing)
and E+H (HE) populations. For the initial analyses, we
focused on components of key signaling pathways implicated
in HSC development and found that the expression levels
of b-catenin and many Wnt target genes were significantly
lower in E+H+ cells compared to E+H cells (Figure 6A). Ana-
lyses of E10.5 E+ cells treated with either ATRA or AM580
showed that RA signaling led to a downregulation of expression
of components of the Wnt signaling pathway in E10.5 E+
cells to levels similar to those found in the E11.5 E+H+ cells
(Figure 6B).
To further investigate the status of Wnt signaling in E11.5
AGM, E+H, E+H+ and E-H+ populations were analyzed by
intracellular flow cytometry for their content of total and phos-
phorylated (Serine 33, 37, and 45; Tyrosine 41) b-catenin, a
downstream mediator of the canonical Wnt signaling (Clevers,220 Cell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc.2006). The total b-catenin levels were highest in the E+H pop-
ulation, and gradually decreased with the acquisition of the
hematopoietic marker CD45, and the loss of endothelial
markers AA4.1 and VEC. Increase in the ratio of phosphorylated
b-catenin to total b-catenin, a hallmark for degradation of
b-catenin, was predominantly observed in the E+H+ fraction
that exclusively contains the developing HSCs (Figures 6C
and 6D).
Immunohistochemistry analyses of E11.5 embryos demon-
strated the presence of the b-catenin protein in the cells lining
the dorsal aorta as well as in the mesenchyme surrounding it
(Figure 6E, i). Although the majority of the protein was present
at the cell surface and within the cytoplasm, low amounts could
be detected in the nucleus, suggesting that the Wnt pathway is
active within these cells at this stage of development (Figure 6E,
i and ii). In contrast to cells lining the aorta, the hematopoietic
cells within it, as well as those that appear to be budding do
not contain any detectable b-catenin protein. These observa-
tions are consistent with the intracellular flow analyses and sup-
port the interpretation that the downregulation of the b-catenin
protein correlates with the emergence of HSCs within the dorsal
aorta. Collectively, these findings strongly suggest that inhibition
of the Wnt pathway is associated with HSC development and
that the effects of RA signaling may be mediated through this
pathway.
To determine whether the downregulation of Wnt signaling is
required for the RA-mediated enhancement of HSCs we treated
the E10.5 AGM-derived E+ cells with AM580, the Wnt
agonist CHIR99021 (Sato et al., 2004), the Wnt antagonists
(iWP2+iCRT14) (Chen et al., 2009a; Gonsalves et al., 2011), or
combinations of these modulators prior to transplantation. As
expected, treatment with AM580 increased HSC potential (m =
62.5%, p < 0.05, f = 80%) compared to the DMSO control (m =
9.2, f = 40%) (Figures 7A and 7B). If Wnt signaling is downstream
Figure 5. RAR-a Selectively Promotes HSC Development from pre-HSC Progenitors Identified by Aldehyde Dehydrogenase Activity
(A) Schematic of transplantation assays with the different E10.5 AGM-derived isolated cell populations (i and ii) cultured in the presence of RA modulators.
(B) Analysis of donor-derived cells in PB at 16 weeks posttransplantation from 3 e.e. The dashed line represents 5% donor-derived chimerism.
Significant difference in percent donor-derived PB cells was observed between AM580 DMSO treated cells (**p < 0.01, ANOVA, and Dunnett’s postmultiple
comparison).
(C) LDA with 0.1, 0.3, 1, and 3 e.e. treated with AM580 (black solid circles, and line) or DMSO (gray solid rectangles, and line). The dashed line represents 95%CI;
for both treatments (p = 6.8 3 105).
(D) Following the experimental scheme in Figure 5A, ii, analysis of donor-derived PB in mice transplanted with 3 e.e. E10.5 E+Aldh population treated with
DMSO (solid circle) or AM580 (solid rectangle), or E10.5 E+Aldh+ population treated with DMSO (solid triangle) or AM580 (solid inverted triangle). Significant
differences from combined DMSO and AM580 treatment of E+Aldh+ and E+Aldh are indicated with asterisks (**p < 0.01, ANOVA, and Dunnett’s postmultiple
comparison test with Aldh+(+DMSO) as the comparative column). See also Tables S1 and S4.and downregulated in the presence of RA signaling, we reasoned
that activating the pathway should abrogate the HSC inductive
effect of RA signaling. Indeed, the effect of RA signaling on
HSC development, as measured by frequency and percent
engraftment, was dramatically inhibited by the addition of
CHIR99021 (m = 6.5%, p < 0.05, f = 40%). Alternatively, if
Wnt signaling is the primary mediator of the RA signaling
pathway, then blocking Wnt signaling alone should mimic HSC
inductive effect of RA signaling. Culture with the Wnt inhibitors
iWP2+iCRT14 did enhance HSC development in the absence
of AM580 (m = 42.6%, p < 0.05, f = 80%). The addition of the
Wnt inhibitors with AM580 did not show a synergistic effect
(m = 37.5%, p > 0.05, f = 80%). Collectively, these observations
support the interpretation that inhibition of the b-catenin/Wnt
pathway, likely via RA signaling, is required for the generation/
development of HSCs.
To investigate the interaction between RA and Wnt signaling
in more detail, we used a mouse ESC line engineered to
contain TOP flash or FOP flash reporters (Lindsley et al.,
2006). The mESCs were differentiated using a serum-free pro-tocol to generate a AA4.1+/VEC+ (E+) population that displays
many characteristics of the E 10.5 AGM population (Irion et al.,
2010; B.C., C.M. Sturgeon, and G.K., unpublished data) (Fig-
ure 7C). The mESC-derived E+ cells were isolated at day 6
of differentiation, treated for 24 hr with modulators of the
Wnt and RA pathway, and then analyzed for Wnt/b-catenin
activity. Addition of ATRA or AM580 in both the presence
(p < 0.01) or absence (p < 0.01) of the Wnt agonist
(CHIR99021) significantly reduced the TOP/FOP flash activity,
in some cases to levels lower than those detected following
the addition of the Wnt antagonists (IWP2 and iCRT14) (Fig-
ure 7D). These findings demonstrate that RA signaling can
inhibit the Wnt/b-catenin pathway in mESC-derived HE-like
progenitors in vitro. To investigate whether the Wnt and RA
signaling pathway can directly interact in the ESC-derived pro-
genitors, we stimulated ESC-derived day 6.0 E+ cells for 24 hr
with ATRA and performed immunoprecipitation of the b-catenin
protein followed by western blot analyses to detect possible
association between the RAR-a and b-catenin protein. As
shown in Figures 7E and 7F, the RAR-a protein was detectedCell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc. 221
Figure 6. Wnt Signaling Is Downregulated
during HSC Development
(A) Heat maps showing differential expression of
Wnt target genes between E11.5 E+H and E+H+
cells. Red and blue indicates upregulation and
downregulation, respectively, of a given gene
normalized to background intensity. Biological
replicates are indicated at the top of each column,
and genes are indicated on the right side.
(B) qRT-PCR-based analysis showing the ex-
pression of Wnt target genes in pre-HSC (E10.5)
and HSC (E11.5) containing fractions with or
without exposure to RA signaling modulators.
Asterisks indicate significant differences com-
pared to the DMSO control, and error bars repre-
sent the SEM (*p < 0.05, **p < 0.01, ***p < 0.001,
t test).
(C) Intracellular flow cytometric analysis of E11.5
AGM-derived (i) E+H (blue rectangle), E+H+
(green rectangle) and EH+ (red rectangle) pop-
ulations to monitor (ii) total b-catenin and (iii)
phospho b-catenin, respectively.
(D) Quantitative analysis from three independent
experiments to determine the percentage of
E+H, E+H+ and EH+ cells with total and
phospho-b-catenin. Asterisks indicate significant
differences, and error bars represent the SEM (*p <
0.05, **p < 0.01, ***p < 0.001, t test).
(E) Confocal microscopy showing distribution of
the b-catenin protein in E11.5 AGM region. (i)
The area of interest is highlighted with a white
rectangle. Red dashed line indicate nuclear
region. (ii) Asterisks indicate cells of interest,
whereas area of interest is highlighted with a
black rectangle. The lining of the aorta is indi-
cated with dashed white lines. Blue, DAPI; yel-
low, b-catenin. Bars represent the scale of the
respective image.in the b-catenin-derived precipitate from cells treated with
ATRA, indicating that the two proteins can interact in a ligand
dependent manner.222 Cell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc.DISCUSSION
Understanding the signaling pathways
that regulate the key steps in the develop-
ment of HSCs in the early embryo,
including the formation of HE and its tran-
sition to a hematopoietic/HSC fate is
essential for enabling us to accurately
model hematopoietic development in
pluripotent stem cell differentiation cul-
ture and to ultimately generate functional
HSCs in vitro. In this study, we defined a
role for the RA signaling pathway in this
developmental progression and demon-
strate it is essential for HSC develop-
ment. A key aspect of our studies was
the observation that activation of the RA
pathway enhances the HSC potential of
the E10.5 AA4.1+/VEC+ HE/pre-HSCsand that this effect is restricted to the fraction of the population
that displays active aldehyde dehydrogenase activity. These
findings identify a signaling pathway that acts directly within
Figure 7. HSC Inductive Effect of Retinoic
Acid Signaling Is Modulated by b-catenin
Dependent Wnt Signaling
(A) Analysis of donor-derived PB at 16 weeks
posttransplantation of the E10.5 E+ population
(3 e.e.) treated with modulators of the RA or Wnt
signaling pathways. The dashed line represents
5% donor-derived chimerism. Significant differ-
ences between cells treated with DMSO and
signalingpathwayagonists or antagonists (AM580,
IWP2+iCRT14, CHIR99021, AM580+CHIR99021,
and AM580+ IWP2+iCRT14) are indicated with
black asterisks, whereas differences between the
AM580-treated cells and cells treated with other
pathway modulators are indicated with red
asterisks (**p < 0.01, and *p < 0.05 ANOVA, and
Dunnett’s postmultiple comparison test with
DMSO or AM580 as comparative columns).
(B) Frequency of mice displaying > 5% donor-
derived PB in response toWnt andRAmodulators.
(C) Schematic of approach used to monitor Wnt
signaling in response to treatment with RA sig-
naling modulators in ESC-derived AA4.1+/VEC+
endothelial/hematopoietic progenitors.
(D) Relative fold change in the ratio of TOP/FOP
flash activity in response to modulators of RA and
Wnt signaling. Significant differences between
cells treated with DMSO and signaling pathway
agonists or antagonists (ATRA, AM580 and
IWP2+iCRT14) in the absence (open columns) or
presence (solid columns) of the Wnt agonist
CHIR99021 are indicated with black and red
asterisks, respectively (***p < 0.001, **p < 0.01,
and *p < 0.05; t test).
(E) Blot showing interaction of b-catenin with
RAR-a. Samples from nuclear lysates obtained
from mESC-derived E+ cells treated with or
without RA were immunoprecipitated with anti-
b-catenin, and then blotted with anti-RAR-a and
anti-b-catenin.
(F) Quantification of the RAR-a and b-catenin
protein interaction in the presence or absence of
ATRA (***p < 0.001, t test).
(G) Model summarizing interaction of RA and
Wnt signaling during commitment of hemogenic
endothelium to HSCs and hematopoietic pro-
genitors. See also Table S1.the isolated HE target population to promote HSC development.
Additionally, we provide in vivo and in vitro evidence that theWnt
pathway is a downstream target of RA signaling in this popula-
tion and show that transient downregulation of b-catenin depen-
dent Wnt signaling is essential for mediating RA’s effect on HSC
development. Together these observations support a model
(Figure 7G) of dynamic regulation of Wnt/b-catenin by RA in HE
(AA4.1+/VEC+CD45-Aldh+) progenitors, initiating a sequence
of events that promotes rapid maturation/development of the
HSC (AA4.1+/VEC+CD45+Aldh+).
Characterization of the signaling pathways that regulate HSC
development within the AGM is challenging as this region of
the embryo consists of multiple different cell types, with HE
and the developing HSCs representing a minority of the entire
population. Given this complexity, it is virtually impossible to
discriminate between direct and indirect effects of cytokineswhen added to mixed populations or intact tissues in vitro. To
overcome this problem, we focused all of our studies on isolated
enriched populations and were able to demonstrate that activa-
tion of RA signaling in E10.5 E+ progenitors enhanced their HSC
potential by more than 5-fold. Importantly, we further demon-
strate that this pro-HSC effect is restricted to the fraction of
the population that displays aldehyde dehydrogenase activity.
At E11.5, aldehyde dehydrogenase activity defines the HSC sub-
population of VEC/AA4.1+CD45+ cells and distinguished it from
the Aldh fraction that contains the majority of multipotent and
GM progenitors. Together, these findings support the interpreta-
tion that aldehyde dehydrogenase activity uniquely identifies the
HE that will give rise to HSCs and distinguishes it from HE that
generates hematopoietic progenitors. The concept of distinct
HE giving rise to HSCs and hematopoietic progenitors within
the AGM is supported by the findings of Chen and Speck whoCell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc. 223
showed that the transcriptional regulation of these populations
differs (Chen et al., 2011). Both human cord blood and adult
mouse marrow-derived HSCs are also Aldh+, suggesting that
the capacity to synthesize RA is a feature of HSCs that is main-
tained beyond the early specification stage (Armstrong et al.,
2004; Hess et al., 2004).
Previous studies have provided evidence that the RA pathway
does play a role in embryonic hematopoiesis. In an in-vitro-
based study using the hESC differentiation model, Yu et al.
showed that RA signaling promoted the generation of CD45+
cells, and myeloid and erythroid progenitors from hematovascu-
lar progenitors isolated from the differentiation cultures (Yu et al.,
2010). In an earlier study, Goldie et al. analyzed the yolk sacs of
E9.5 Raldh2 null embryos and reported defects in a population
defined as HE that displayed myeloid and erythroid hematopoi-
etic potential, suggesting that RA signaling played a role in the
generation of these progenitors (Goldie et al., 2008). Although
these latter observations support a role for RA signaling in em-
bryonic hematopoietic specification, the interpretation of the
phenotype is complicated by the fact that Raldh2 null embryos
show broad vascular defects and are embryonic lethal at the
stage they were characterized or shortly thereafter. To circum-
vent this problem, we selectively deleted the Raldh2 gene in
the VEC+ population and demonstrated that Raldh2 is essential
for HSC development. The Raldh2f/f;VEC-Cre deleted embryos
did not show dramatic abnormalities and had intact dorsal aorta
lined with VEC+ cells, indicating that the absence of HSCs is not
due to extensive morphological or endothelial-specific defects
within the AGM. Rather, our ex vivo studies point to a role for
RA signaling within the Aldh+ HE/pre-HSC population either
through promoting proliferation of low numbers of HSC already
present or by initiating a sequence of maturation events. The
fact that the effect was most pronounced on the E10.5 pop-
ulation, which contains fewer HSCs than the E11.5 fraction,
suggests that RA signaling induces maturation of a HE to
the HSC.
Through the use of different pathway agonists we were able to
demonstrate a striking degree of receptor specificity for the
enhancement of HSCs ex vivo and identified RAR-a as the pri-
mary receptor mediating this effect. The lack of an effect of the
RAR-g agonist is somewhat unexpected, given that the receptor
is expressed in the target population at the appropriate develop-
mental stage. This expression pattern suggests that under
certain circumstances, such as in RAR-a null embryos, it may
provide a compensatory function to promote HSC development.
This interpretation would be consistent with the observation that
RAR-a null mice are viable with no gross developmental hemato-
poietic defects, whereas the RAR-a/RAR-g compound mutants
are embryonic lethal (Mark et al., 2009; Rhinn and Dolle´, 2012).
Although RAR-a agonist showed a striking HSC inductive effect,
neither RAR-a nor RAR-g expression level varied between the
E+H and E+H+ populations (data not shown). A differential
function of these receptors has also been demonstrated in adult
hematopoiesis, where RAR-g, but not RAR-a, has been shown to
play a role in the maintenance of the adult HSC population (Pur-
ton et al., 2006; Walkley et al., 2007). As observed with the AGM
HE, both receptors are expressed in the adult HSCs. We found
that all RARs are expressed in the E13.5 AA4.1+ fetal liver pop-224 Cell 155, 215–227, September 26, 2013 ª2013 Elsevier Inc.ulation and that both RAR-a and RAR-g agonists modestly
enhanced the repopulation potential of these cells (Figure S3).
Collectively, these observations highlight important differences
in embryonic, fetal and adult hematopoiesis, and support a
model in which different RARs function to regulate HSC develop-
ment, expansion and maintenance at different stages of devel-
opment and in adult life.
Our observation that RA signaling downregulates the Wnt
pathway is consistent with other studies that have shown similar
inhibitory effects on this pathway by retinoid signaling (Easwaran
et al., 1999; Xiao et al., 2003). Easwaran et al. (1999) showed that
the effect could be mediated via direct interaction of b-catenin
with RARs in a retinoid-dependent manner, and/or through
RAR competition with TCF for b-catenin binding. We observed
a similar interaction between the b-catenin and RAR-a protein in
ESC-derived progenitors. A role for Wnt/b-catenin signaling
in the generation of HSC within the AGM has been described
in both the zebrafish and mouse (Goessling et al., 2009; Ruiz-
Herguido et al., 2012). However, in contrast to the findings pre-
sented here, these studies provided evidence that Wnt signaling
promotes HSC development. Although these observations may
at first appear to contradict ours, the differences may be related
to temporal changes in the function of the pathway as the studies
on the mouse AGM indicate that the requirement for Wnt
signaling is stage specific and most pronounced at E10.5 of
gestation prior to the peak of HSC development at E11.5 (Ruiz-
Herguido et al., 2012). This interpretation is consistent with our
findings that the E+H HE population, at E11.5, displays higher
Wnt signaling than the E+H+ HSC population and that b-catenin
is present in the cells lining the dorsal aorta but not in the budding
cells or the hematopoietic cells within the aorta. Collectively,
these observations raise the interesting possibility that signaling
through theWnt pathway is required for the generation of HE, but
thereafter needs to be downregulated to promote HSC develop-
ment (Figure 7G).
In summary, the findings in this study have identified a pivotal
role for RA signaling in the generation of HSCs in the early em-
bryo and provide evidence that it mediates this function through
the inhibition of the Wnt/b-catenin pathway. Additionally, they
show that aldehyde dehydrogenase activity uniquely marks the
pre-HSCs and the HSCswithin the HE and emerging hematopoi-
etic population, respectively, suggesting that these progenitors
display the capacity to synthesize and respond to RA. Together,
these observations provide important insights into the stage-
specific regulation of embryonic HSC development in vivo and
in doing so inform us on key pathways that will need to bemanip-
ulated in embryonic stem cell differentiation cultures to bring us
one step closer to generating HSCs in vitro.
EXPERIMENTAL PROCEDURES
Further details of experimental procedure can be found in the Extended Exper-
imental Procedures.
Embryo Generation and Transplantation Assay
All experiments with animals were performed according to the University
Health Network Animal Resource Center’s guidelines. Timed matings were
performed to generate embryos, with vaginal plug discovery as embryonic
day (E) 0.5. Embryos with 32–40 somite pairs were staged as E10.5, and
42–48 somite pairs as E11.5 for transplantation experiments. Embryos were
dissected at either E10.5 or E11.5 stages for isolation of the AGM, and when
required, the YS and PL. Desired cell populations or whole organs from
embryos were transplanted intrafemorally into recipient mice. Donor-derived
PB was analyzed at 16 or 32 weeks posttransplantation assay.
Conditional Deletion of Raldh2f/f by VEC-Cre
Raldh2f/f and VEC-Cre mice were obtained from Dr. Shanthini Socknathan at
John Hopkins University, and Dr. Nancy Speck at the University of Pennsylva-
nia, respectively. Raldh2f/+; VEC-Cre mice were generated by crossing
of female Raldh2f/f with VEC-Cre male mice, whereas Raldh2f/f;VEC-Cre
conceptus was generated by mating Raldh2f/+; VEC-Cre males with Raldh2f/f
females.
Aldefluor Staining
Aldefluor staining was performed as described elsewhere (Jones et al., 1995)
(Stem Cell Technologies). Briefly, AGM regions were dissected and stained
with aldefluor or DEAB+ aldefluor as negative control, at 37C for 30 min fol-
lowed by staining with anti-mouse VEC, AA4.1, and CD45 antibodies.
Flow Cytometry
Desired cell populations were washed and Fc receptors were blocked by
addition of anti-CD16/32 (eBioscience E03558-1632). Cells were then stained
with desired antibodies; anti-VEC (eBioscience E08593-1630), anti-AA4.1
(eBioscience E01895-186), and anti-CD45 (eBioscience E10032-1631). Spe-
cific cell-populations were sorted on a FACS Aria (BD Biosciences), whereas
they were analyzed on an LSR II flow cytometer (BD Biosciences), and the
data were processed with FlowJo 9.5.3 (Tree Star).
Microarray Analyses
Mouse WG-6 v2 Bead chip from Illumina was used to monitor global gene
expression from high quality RNA (RNA integrity number > 9.0) extracted
from E11.5 E+H+ and E+H cells. Nonnormalized summary probe profiles
(including regular probe profile and control probe profile), with associated
probe annotation, were output from Bead Studio. We then performed
normexp-by-control background correction, quantile normalization and log2
transformation to the raw data using the neqc function in linear models for
microarray data (LIMMA) R package. False discovery rate (FDR) was evaluated
using the Benjamini and Hochberg multiple testing procedure. Heat maps
were generated using Dchip software with centroid linkage, expression by
peaking time and 1- Pearson correlation as significance.
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The GEO accession number for the microarray data is GSE45020.
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